William D. Waddill - 10 Sep 2024 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill
Issuer symbol
PTGX
Transactions as of
10 Sep 2024
Net transactions value
-$256,960
Form type
4
Filing time
12 Sep 2024, 19:38:43 UTC
Previous filing
26 Jul 2024
Next filing
18 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $103,040 +8,000 +67% $12.88 20,000 10 Sep 2024 Direct
transaction PTGX Common Stock Sale $360,000 -8,000 -40% $45.00 12,000 10 Sep 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -8,000 -100% $0.000000 0 10 Sep 2024 Common Stock 8,000 $12.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023.
F2 These stock options are fully vested.